AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

23.15USD
1 Aug 2013
Price Change (% chg)

$0.65 (+2.89%)
Prev Close
$22.50
Open
$23.15
Day's High
$23.15
Day's Low
$23.15
Volume
1,531
Avg. Vol
36,827
52-wk High
$25.63
52-wk Low
$13.90

AMAG.OQ

Chart for AMAG.OQ

About

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of... (more)

Overall

Beta: 0.59
Market Cap (Mil.): $485.44
Shares Outstanding (Mil.): 21.58
Dividend: --
Yield (%): --

Financials

  AMAG.OQ Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -0.38 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

CORRECTED-Amag investigates anemia drug after report of death in Switzerland

(Corrects headline to "investigates." Amag did not say the drug caused the fatality.)

21 May 2013

Amag says anemia drug caused fatal reaction in Switzerland

- Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, Rienso, because of a death and several cases of hypersensitivity.

21 May 2013

Amag says anemia drug caused fatal reaction in Switzerland

May 21 - Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, Rienso, because of a death and several cases of hypersensitivity.

21 May 2013

Austria's B&C makes 23.40 eur takeover offer for AMAG

FRANKFURT, March 11 - Austrian investment group B&C Industrieholding GmbH said it will make a mandatory takeover offer of 23.40 euros to shareholders in aluminium group AMAG .

11 Mar 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$472.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks